Brian L Erstad

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1873483/publications.pdf

Version: 2024-02-01

232693
48
dex g-index
36 2656
ranked citing authors
citing autiors

#	Article	IF	CITATIONS
1	Considerations When Using Body Mass Index as a Size Descriptor. Annals of Pharmacotherapy, 2023, 57, 107-109.	0.9	1
2	Usefulness of the Biomarker TIMP-2•IGFBP7 for Acute Kidney Injury Assessment in Critically Ill Patients: A Narrative Review. Annals of Pharmacotherapy, 2022, 56, 83-92.	0.9	4
3	Teaching Ethics: See One, Do One, … Teach One?. American Journal of Pharmaceutical Education, 2022, 86, 8503.	0.7	O
4	Ethical Decision-Making in the Pharmacists' Patient Care Process. American Journal of Pharmaceutical Education, 2022, 86, 8655.	0.7	1
5	Normal saline or balanced salt solutions for fluid administration with a focus on critical care and emergency medicine settings. American Journal of Health-System Pharmacy, 2022, 79, 199-203.	0.5	O
6	Response to Murray et al. American Journal of Health-System Pharmacy, 2022, 79, 16-16.	0.5	0
7	Antibiotic prophylaxis for traumatic facial fractures. Journal of Clinical Pharmacy and Therapeutics, 2022, 47, 386-395.	0.7	5
8	Multicenter Retrospective Review of Ketamine Use in the ICU., 2022, 4, e0633.		7
9	Influence of Timing and Catecholamine Requirements on Vasopressin Responsiveness in Critically ill Patients with Septic Shock. Journal of Intensive Care Medicine, 2022, 37, 1512-1519.	1.3	7
10	Implications of obesity for drug administration and absorption from subcutaneous and intramuscular injections: A primer. American Journal of Health-System Pharmacy, 2022, 79, 1236-1244.	0.5	4
11	Drug dosing in hospitalized obese patients with COVID-19. Critical Care, 2022, 26, 60.	2.5	3
12	Professional volunteerism: Try it, you will like it. JACCP Journal of the American College of Clinical Pharmacy, 2022, 5, 388-389.	0.5	0
13	Balanced Salt Solutions for Critically Ill Patients: Nonplused and Back to Basics. Annals of Pharmacotherapy, 2022, 56, 1365-1375.	0.9	5
14	Cost-Effectiveness and Economic Burden Analyses on All First-Line Treatments of Chronic Lymphocytic Leukemia. Value in Health, 2022, 25, 1685-1695.	0.1	6
15	Appraising the use of tranexamic acid in traumatic and nonâ€traumatic intracranial hemorrhage: A narrative review. Journal of the American College of Emergency Physicians Open, 2022, 3, .	0.4	1
16	Pitfalls and pearls with drug dosing in the critically ill obese patient: 10 statements to guide ICU practitioners. Journal of Critical Care, 2022, 71, 154105.	1.0	2
17	Assessment of Kidney Function in Patients With Extreme Obesity: A Narrative Review. Annals of Pharmacotherapy, 2021, 55, 80-88.	0.9	9
18	Clinical Pharmacist–Led Impact on Inappropriate Albumin Utilization and Associated Costs in General Ward Patients. Annals of Pharmacotherapy, 2021, 55, 44-51.	0.9	7

#	Article	IF	CITATIONS
19	Ex Ante Economic Evaluation of Arg389 Genetically Targeted Treatment with Bucindolol versus Empirical Treatment with Carvedilol in NYHA III/IV Heart Failure. American Journal of Cardiovascular Drugs, 2021, 21, 205-217.	1.0	3
20	Initiation of Oseltamivir in Critically III Patients: Variations in Prescribing Practices. Annals of Pharmacotherapy, 2021, 55, 265-266.	0.9	1
21	Sensorineural hearing loss with macrolide antibiotics exposure: a meta-analysis of the association. International Journal of Pharmacy Practice, 2021, 29, 21-28.	0.3	12
22	Serum Albumin Levels: Who Needs Them?. Annals of Pharmacotherapy, 2021, 55, 798-804.	0.9	20
23	Caring for the COVID Patient: A Clinical Pharmacist's Perspective. Annals of Pharmacotherapy, 2021, 55, 413-414.	0.9	4
24	Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER–Medicare database. Therapeutic Advances in Drug Safety, 2021, 12, 204209862199127.	1.0	1
25	Predicted body weight: A rose by any other name. American Journal of Health-System Pharmacy, 2021, 78, 751-753.	0.5	2
26	Drug dosing in the critically ill obese patient: a focus on medications for hemodynamic support and prophylaxis. Critical Care, 2021, 25, 77.	2.5	15
27	Caveats in Kidney Function Assessment. Annals of Pharmacotherapy, 2021, 55, 1419-1422.	0.9	0
28	Creatinine Assessment in Non–Steady-State Conditions: A Critical Review. Annals of Pharmacotherapy, 2021, 55, 1536-1544.	0.9	0
29	Dosing of neuromuscular blocking agents in patients with obesity: A narrative review. Anaesthesia and Intensive Care, 2021, 49, 98-104.	0.2	8
30	Proposed guidance on cost-avoidance studies in pharmacy practice. American Journal of Health-System Pharmacy, 2021, 78, 1559-1567.	0.5	15
31	Methods used to attribute costs avoided from pharmacist interventions in acute care: A scoping review. American Journal of Health-System Pharmacy, 2021, 78, 1576-1590.	0.5	10
32	Comparative Efficacy of First-Line Treatments of Chronic Lymphocytic Leukemia: Network Meta-Analyses of Survival Curves. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e820-e831.	0.2	8
33	Albumin for cirrhosisâ€related complications. Journal of Clinical Pharmacy and Therapeutics, 2021, 46, 887-894.	0.7	1
34	Survival trends in chronic lymphocytic leukemia across treatment eras: US SEER database analysis (1985–2017). Annals of Hematology, 2021, 100, 2501-2512.	0.8	13
35	Response to †Drug dosage in patients with obesity: Investigation of lean body mass'. Anaesthesia and Intensive Care, 2021, , 0310057X2110345.	0.2	0
36	Clinical outcomes of concomitant use of enteral and intravenous sedatives and analgesics in mechanically ventilated patients with COVID-19. American Journal of Health-System Pharmacy, 2021, , .	0.5	2

#	Article	IF	CITATIONS
37	Critical care essentials for pharmacy trainees and new clinical practitioners. American Journal of Health-System Pharmacy, 2021, 78, 1176-1183.	0.5	2
38	Ten Tips for Pharmacy Faculty Members for Successfully Navigating Promotion and Tenure. American Journal of Pharmaceutical Education, 2021, 85, 8414.	0.7	4
39	Equity for and Inclusion of Non-Tenure-Track Pharmacy Faculty Within Academia. American Journal of Pharmaceutical Education, 2021, 85, 8428.	0.7	4
40	Economic evaluation using dynamic transition modeling of ebola virus vaccination in lower-and-middle-income countries. Journal of Medical Economics, 2021, 24, 1-13.	1.0	4
41	Extremely hypo-osmolar intravenous solutions to treat hypernatremia: The time has come to stop. American Journal of Health-System Pharmacy, 2021, , .	0.5	0
42	Clinical Pharmacist–Led Impact on Inappropriate Albumin Use and Costs in the Critically Ill. Annals of Pharmacotherapy, 2020, 54, 105-112.	0.9	16
43	Pharmacists and the opioid crisis: A narrative review of pharmacists' practice roles. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 478-484.	0.5	28
44	Targeted Temperature Management: Quantifying the Extent of Serum Electrolyte and Blood Glucose Shifts in Postcardiac Arrest Patients. Therapeutic Hypothermia and Temperature Management, 2020, 10, 76-81.	0.3	5
45	Corticosteroid Tapering Regimens in Rheumatic Disease. Journal of Clinical Rheumatology, 2020, 26, 41-47.	0.5	7
46	Pricing methods in outcome-based contracting: Î'4: safety-based pricing. Journal of Medical Economics, 2020, 23, 1237-1245.	1.0	4
47	Pricing methods in outcome-based contracting: Î'5: risk of efficacy failure-based pricing. Journal of Medical Economics, 2020, 23, 1246-1255.	1.0	4
48	Pricing methods in outcome-based contracting: Î'1: cost effectiveness analysis and cost-utility analysis-based pricing. Journal of Medical Economics, 2020, 23, 1215-1222.	1.0	8
49	Pricing methods in outcome-based contracting: Î'2: willingness-to-pay-based pricing. Journal of Medical Economics, 2020, 23, 1223-1229.	1.0	7
50	Pricing methods in outcome-based contracting: Î'6: adherence-based pricing. Journal of Medical Economics, 2020, 23, 1256-1265.	1.0	4
51	Pricing methods in outcome-based contracting: integration analysis of the six dimensions (6 $\hat{\Gamma}$ s). Journal of Medical Economics, 2020, 23, 1266-1272.	1.0	6
52	Pricing methods in outcome-based contracting: Î'3: reference-based pricing. Journal of Medical Economics, 2020, 23, 1230-1236.	1.0	9
53	Cost Analysis of Adjunctive Hydrocortisone Therapy for Septic Shock: U.S. Payer Perspective. Critical Care Medicine, 2020, 48, e906-e911.	0.4	2
54	Justification of the value of critical care pharmacists: Still a work in progress?. American Journal of Health-System Pharmacy, 2020, 77, 1906-1909.	0.5	12

#	Article	IF	CITATIONS
55	Drug dosing in the critically ill obese patient—a focus on sedation, analgesia, and delirium. Critical Care, 2020, 24, 315.	2.5	42
56	Availability of information for dosing commonly used medications in special ICU populations. American Journal of Health-System Pharmacy, 2020, 77, 529-534.	0.5	11
57	The pharmacist's role in disaster research response. American Journal of Health-System Pharmacy, 2020, 77, 1054-1059.	0.5	2
58	The Revised Starling Equation: The Debate of Albumin Versus Crystalloids Continues. Annals of Pharmacotherapy, 2020, 54, 921-927.	0.9	11
59	Potential Immune-Related Adverse Events Associated With Monotherapy and Combination Therapy of Ipilimumab, Nivolumab, and Pembrolizumab for Advanced Melanoma: A Systematic Review and Meta-Analysis. Frontiers in Oncology, 2020, 10, 91.	1.3	112
60	Raising the interprofessional bar in your specialty interprofessional health care organization. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 398-399.	0.5	3
61	A brief history of pharmacy specialization in the United States. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1464-1470.	0.5	4
62	What it means to be a Clinical Pharmacist: An n of one study. JACCP Journal of the American College of Clinical Pharmacy, 2020, 3, 1006-1008.	0.5	0
63	Implications of the opioid epidemic for critical care practice. JACCP Journal of the American College of Clinical Pharmacy, 2019, 2, 161-166.	0.5	6
64	The Conscience of a Pharmacist. American Journal of Pharmaceutical Education, 2019, 83, 7301.	0.7	5
65	Enhancing Educational and Leadership Opportunities for Second-Year Pharmacy Residents. American Journal of Pharmaceutical Education, 2019, 83, 7099.	0.7	2
66	Systematic Review and Meta-analysis of the Safety of Antistaphylococcal Penicillins Compared to Cefazolin. Antimicrobial Agents and Chemotherapy, 2018, 62, .	1.4	39
67	A cross-sectional study of predictors of pain control during the transition from the surgical intensive care unit to surgical ward. Australian Critical Care, 2018, 31, 159-164.	0.6	8
68	Ex ante economic evaluation of genetic testing for the ARG389 beta1-adrenergic receptor polymorphism to support bucindolol treatment decisions in Stage III/IV heart failure. Expert Review of Precision Medicine and Drug Development, 2018, 3, 319-329.	0.4	3
69	Issues and Opportunities on Implementing an Online Faculty Review System. American Journal of Pharmaceutical Education, 2018, 82, 6911.	0.7	3
70	Economic Evaluation for USA of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics, 2018, 36, 1273-1284.	1.7	9
71	Heparin dosing for venous thromboembolism prophylaxis in obese hospitalized patients: An observational study. Thrombosis Research, 2018, 169, 152-156.	0.8	6
72	Albumin disposition in critically Ill patients. Journal of Clinical Pharmacy and Therapeutics, 2018, 43, 746-751.	0.7	10

#	Article	IF	CITATIONS
73	Economic Evaluation for the UK of Systemic Chemotherapies as First-Line Treatment of Metastatic Pancreatic Cancer. Pharmacoeconomics, 2018, 36, 1333-1343.	1.7	12
74	Ketamine for Analgosedation in the Intensive Care Unit: A Systematic Review. Journal of Intensive Care Medicine, 2017, 32, 387-395.	1.3	48
75	Methocarbamol use is associated with decreased hospital length of stay in trauma patients with closed rib fractures. American Journal of Surgery, 2017, 214, 738-742.	0.9	14
76	Clinical practice guidelines for sustained neuromuscular blockade in the adult critically ill patient: 2016 updateâ€"executive summary. American Journal of Health-System Pharmacy, 2017, 74, 76-78.	0.5	20
77	Development of the Critical Care Pharmacotherapy Trials Network. American Journal of Health-System Pharmacy, 2017, 74, 287-293.	0.5	4
78	Student use of flipped classroom videos in a therapeutics course. Currents in Pharmacy Teaching and Learning, 2017, 9, 50-54.	0.4	16
79	Should estimates of glomerular filtration rate and creatinine clearance be indexed to body surface area for drug dosing?. American Journal of Health-System Pharmacy, 2017, 74, 1814-1819.	0.5	10
80	Evaluation and Treatment of Acute and Subacute Hearing Loss: A Review of Pharmacotherapy. Pharmacotherapy, 2017, 37, 1600-1616.	1.2	5
81	Improving Medication Dosing in the Obese Patient. Clinical Drug Investigation, 2017, 37, 1-6.	1.1	13
82	Comparison of Dexmedetomidine Versus Propofol on Hospital Costs and Length of Stay. Journal of Intensive Care Medicine, 2016, 31, 466-470.	1.3	15
83	Clinical Practice Guidelines for Sustained Neuromuscular Blockade in the Adult Critically Ill Patient. Critical Care Medicine, 2016, 44, 2079-2103.	0.4	297
84	Ketamine for analgosedation in critically ill patients. Journal of Critical Care, 2016, 35, 145-149.	1.0	61
85	Succinylcholine Is Associated with Increased Mortality When Used for Rapid Sequence Intubation of Severely Brain Injured Patients in the Emergency Department. Pharmacotherapy, 2016, 36, 57-63.	1.2	35
86	Readmissions related to antihypertensive medications used in chronic hemodialysis. Renal Failure, 2016, 38, 40-45.	0.8	4
87	Value-Based Medicine. Critical Care Medicine, 2016, 44, 375-380.	0.4	9
88	Norepinephrine Dosing in Obese and Nonobese Patients With Septic Shock. American Journal of Critical Care, 2016, 25, 27-32.	0.8	20
89	Designing drug regimens for special intensive care unit populations. World Journal of Critical Care Medicine, 2015, 4, 139.	0.8	14
90	Higher insulin infusion rate but not 24-h insulin consumption is associated with hypoglycemia in critically ill patients. Diabetes Research and Clinical Practice, 2015, 110, 322-327.	1.1	0

#	Article	IF	CITATIONS
91	Pharmacoepidemiology of stress ulcer prophylaxis in the United States and Canada. Journal of Critical Care, 2014, 29, 955-960.	1.0	51
92	Comparison of Methods for the Detection of Medication Safety Events in the Critically Ill. Current Drug Safety, 2012, 7, 238-246.	0.3	1
93	Pharmacoepidemiology and patient safety in the critically ill. Pharmaceuticals Policy and Law, 2012, 14, 93-104.	0.1	O
94	Interdisciplinary Patient Care in the Intensive Care Unit: Focus on the Pharmacist. Pharmacotherapy, 2011, 31, 128-137.	1.2	35
95	A Comparison of Automated Infusion Device Technology to Prevent Medication Errors in Pediatric and Adult Intensive Care Unit Patients. Hospital Pharmacy, 2010, 45, 464-471.	0.4	10
96	Developing models for pharmacy practice. American Journal of Health-System Pharmacy, 2010, 67, 23-24.	0.5	6
97	Availability of information for dosing injectable medications in underweight or obese patients. American Journal of Health-System Pharmacy, 2010, 67, 1948-1950.	0.5	31
98	Pain Management Principles in the Critically Ill. Chest, 2009, 135, 1075-1086.	0.4	130
99	Evaluation of Pain in ICU Patients. Chest, 2009, 135, 1069-1074.	0.4	115
100	Key Articles and Guidelines Relative to Intensive Care Unit Pharmacotherapy: 2009 Update. Pharmacotherapy, 2009, 29, 1228-1269.	1.2	10
101	Pain Management Within the Palliative and End-of-Life Care Experience in the ICU. Chest, 2009, 135, 1360-1369.	0.4	60
102	Comparison of Opioid Requirements and Analgesic Response in Opioidâ€Tolerant versus Opioidâ€NaÃ⁻ve Patients After Total Knee Arthroplasty. Pharmacotherapy, 2008, 28, 1453-1460.	1.2	65
103	A Primer on Critical Care Pharmacy Services. Annals of Pharmacotherapy, 2008, 42, 1871-1881.	0.9	24
104	Cost-effectiveness of linezolid and vancomycin in the treatment of surgical site infections. Current Medical Research and Opinion, 2007, 23, 185-193.	0.9	25
105	Cost implications of and potential adverse events prevented by interventions of a critical care pharmacist. American Journal of Health-System Pharmacy, 2007, 64, 2483-2487.	0.5	157
106	Pharmacologic Management of Constipation in the Critically Ill Patient. Pharmacotherapy, 2006, 26, 896-902.	1.2	48
107	Accuracy and reproducibility of small-volume injections from various-sized syringes. American Journal of Health-System Pharmacy, 2006, 63, 748-750.	0.5	18
108	Key Articles and Guidelines Relative to Intensive Care Unit Pharmacology—2004. Pharmacotherapy, 2005, 25, 585-610.	1.2	5

#	Article	IF	Citations
109	What is the evidence for using hemostatic agents in surgery?. European Spine Journal, 2004, 13, S28-S33.	1.0	6
110	Dosing of medications in morbidly obese patients in the intensive care unit setting. Intensive Care Medicine, 2004, 30, 18-32.	3.9	149
111	Prescribing and Self-Administration of Morphine in Hispanic and Non-Hispanic Caucasian Patients Treated with Patient-Controlled Analgesia. Journal of Pain and Palliative Care Pharmacotherapy, 2004, 18, 29-38.	0.5	7
112	Cost-effectiveness of proton pump inhibitor therapy for acute peptic ulcer-related bleeding*. Critical Care Medicine, 2004, 32, 1277-1283.	0.4	34
113	Prescribing and Self-Administration of Morphine in Hispanic and Non-Hispanic Caucasian Patients Treated with Patient-Controlled Analgesia. Journal of Pain and Palliative Care Pharmacotherapy, 2004, 18, 29-38.	0.5	1
114	Osmolality and Osmolarity: Narrowing the Terminology Gap. Pharmacotherapy, 2003, 23, 1085-1086.	1.2	48
115	The Cost of Enhanced Acid Suppression. Pharmacotherapy, 2003, 23, 94S-100S.	1.2	1
116	Dyspepsia: Initial Evaluation and Treatment. Journal of the American Pharmacists Association, 2002, 42, 460-468.	0.6	1
117	Implications of prion-induced diseases for animal-derived pharmaceutical products. American Journal of Health-System Pharmacy, 2002, 59, 254-260.	0.5	4
118	The Use of Metoclopramide in Ileus: A Look at Duration of Therapy. Hospital Pharmacy, 2002, 37, 949-952.	0.4	0
119	Which weight for weight-based dosage regimens in obese patients?. American Journal of Health-System Pharmacy, 2002, 59, 2105-2110.	0.5	24
120	Principles and Practice of Pharmacology for Anaesthetists, Fourth Edition. American Journal of Health-System Pharmacy, 2002, 59, 1575-1576.	0.5	2
121	Key Articles and Guidelines Relative to Intensive Care Unit Pharmacology. Pharmacotherapy, 2002, 22, 1594-1610.	1.2	2
122	Medication administration errors in adult patients in the ICU. Intensive Care Medicine, 2001, 27, 1592-1598.	3.9	158
123	Proton-Pump Inhibitors for Acute Peptic Ulcer Bleeding. Annals of Pharmacotherapy, 2001, 35, 730-740.	0.9	26
124	Antifibrinolytic Agents and Desmopressin as Hemostatic Agents in Cardiac Surgery. Annals of Pharmacotherapy, 2001, 35, 1075-1084.	0.9	36
125	Systemic Hemostatic Medications for Reducing Surgical Blood Loss. Annals of Pharmacotherapy, 2001, 35, 925-934.	0.9	38
126	Octreotide for Acute Variceal Bleeding. Annals of Pharmacotherapy, 2001, 35, 618-626.	0.9	20

#	Article	IF	CITATIONS
127	Enteral Nutrition Support in Acute Pancreatitis. Annals of Pharmacotherapy, 2000, 34, 514-521.	0.9	17
128	Treatment of Hypertension in the Perioperative Patient. Annals of Pharmacotherapy, 2000, 34, 66-79.	0.9	23
129	Concerns with defining appropriate uses of albumin by meta-analysis. American Journal of Health-System Pharmacy, 1999, 56, 1451-1454.	0.5	14
130	Influence of twenty-five per cent human serum albumin on total and ionized calcium concentrations in vivo. Critical Care, 1999, 3, 117.	2.5	4
131	Development of algorithms for treating patients in the intensive care unit. American Journal of Health-System Pharmacy, 1997, 54, 1841-1845.	0.5	7
132	Management of alcohol withdrawal. American Journal of Health-System Pharmacy, 1995, 52, 697-709.	0.5	194
133	Adverse Gastrointestinal Effects of Nonsteroidal Anti-Inflammatory Drugs. Journal of Pharmacy Practice, 1994, 7, 144-153.	0.5	0
134	Effect of fixed-dose hydrocortisone on vasopressor dose and mean arterial pressure in obese and nonobese patients with septic shock. American Journal of Health-System Pharmacy, 0, , .	0.5	1
135	Quality of critical care clinical practice guidelines involving pharmacotherapy recommendations. American Journal of Health-System Pharmacy, 0, , .	0.5	2